Do analysts recommend XBIO or ATNM?

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 309.84%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to XBIO or ATNM?

In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 5 mentions for Xenetic Biosciences. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Xenetic Biosciences' score of 0.11 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XBIO or ATYR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media refer more to XBIO or ATYR?

In the previous week, Xenetic Biosciences had 4 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for aTyr Pharma. Xenetic Biosciences' average media sentiment score of 0.11 beat aTyr Pharma's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CELU or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CELU or XBIO?

In the previous week, Xenetic Biosciences had 4 more articles in the media than Celularity. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for Celularity. Xenetic Biosciences' average media sentiment score of 0.11 beat Celularity's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CNTX or XBIO?

In the previous week, Xenetic Biosciences had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for Context Therapeutics. Xenetic Biosciences' average media sentiment score of 0.11 beat Context Therapeutics' score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer XBIO or MDXH?

MDxHealth has a consensus price target of $2.17, indicating a potential upside of 243.92%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer XBIO or MDXH?

In the previous week, Xenetic Biosciences had 4 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for MDxHealth. Xenetic Biosciences' average media sentiment score of 0.11 beat MDxHealth's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Xenetic Biosciences (XBIO) Competitors

$2.77 +0.31 (+12.60%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.70 -0.07 (-2.67%)

As of 09/18/2026 07:53 PM Eastern

Compare

XBIO vs. ATNM, ATYR, CELU, CNTX, and MDXH

Should you buy Xenetic Biosciences stock or one of its competitors? Xenetic Biosciences's main competitors and comparable companies include Actinium Pharmaceuticals (ATNM), aTyr Pharma (ATYR), Celularity (CELU), Context Therapeutics (CNTX), and MDxHealth (MDXH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Xenetic Biosciences (NASDAQ:XBIO) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 5 mentions for Xenetic Biosciences. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Xenetic Biosciences' score of 0.11 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenetic Biosciences has higher earnings, but lower revenue than Actinium Pharmaceuticals. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.26M	1.95	-$2.68M	-$1.16	N/A
Actinium Pharmaceuticals	$35.09M	1.09	-$48.82M	$0.36	3.39

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 309.84%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xenetic Biosciences has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats Xenetic Biosciences on 10 of the 16 factors compared between the two stocks.

How does Xenetic Biosciences compare to aTyr Pharma?

Xenetic Biosciences (NASDAQ:XBIO) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

aTyr Pharma has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
aTyr Pharma	N/A	-95.89%	-69.67%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Xenetic Biosciences had 4 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for aTyr Pharma. Xenetic Biosciences' average media sentiment score of 0.11 beat aTyr Pharma's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xenetic Biosciences has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Xenetic Biosciences has higher revenue and earnings than aTyr Pharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.26M	1.95	-$2.68M	-$1.16	N/A
aTyr Pharma	$190K	187.40	-$74.12M	-$0.62	N/A

Summary

Xenetic Biosciences and aTyr Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Xenetic Biosciences compare to Celularity?

Celularity (NASDAQ:CELU) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Xenetic Biosciences has lower revenue, but higher earnings than Celularity. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.43	-$91.72M	-$3.33	N/A
Xenetic Biosciences	$3.26M	1.95	-$2.68M	-$1.16	N/A

Xenetic Biosciences has a net margin of -75.90% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Celularity has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Xenetic Biosciences had 4 more articles in the media than Celularity. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for Celularity. Xenetic Biosciences' average media sentiment score of 0.11 beat Celularity's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Xenetic Biosciences beats Celularity on 8 of the 13 factors compared between the two stocks.

How does Xenetic Biosciences compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Context Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

Context Therapeutics currently has a consensus target price of $6.17, suggesting a potential upside of 1,575.27%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Context Therapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Xenetic Biosciences had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for Context Therapeutics. Xenetic Biosciences' average media sentiment score of 0.11 beat Context Therapeutics' score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Xenetic Biosciences has higher revenue and earnings than Context Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Xenetic Biosciences	$3.26M	1.95	-$2.68M	-$1.16	N/A

Summary

Xenetic Biosciences beats Context Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Xenetic Biosciences compare to MDxHealth?

Xenetic Biosciences (NASDAQ:XBIO) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Xenetic Biosciences has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

Xenetic Biosciences has higher earnings, but lower revenue than MDxHealth. Xenetic Biosciences is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.26M	1.95	-$2.68M	-$1.16	N/A
MDxHealth	$107.88M	0.29	-$33.52M	-$0.72	N/A

15.1% of Xenetic Biosciences shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Xenetic Biosciences had 4 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for Xenetic Biosciences and 1 mentions for MDxHealth. Xenetic Biosciences' average media sentiment score of 0.11 beat MDxHealth's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has a net margin of -33.46% compared to Xenetic Biosciences' net margin of -75.90%. MDxHealth's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
MDxHealth	-33.46%	N/A	-24.25%

MDxHealth has a consensus price target of $2.17, indicating a potential upside of 243.92%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

MDxHealth beats Xenetic Biosciences on 9 of the 16 factors compared between the two stocks.

Get Xenetic Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIO vs. The Competition

Export

Metric	Xenetic Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.35M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-2.39	14.23	275.49	25.40
Price / Sales	1.95	1,434.96	642.70	86.83
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.86	15.45	10.46	6.33
Net Income	-$2.68M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-28.97%	-1.21%	0.59%	1.12%
1 Month Performance	-18.29%	-3.29%	-1.74%	-2.39%
1 Year Performance	-11.50%	37.74%	18.13%	5.35%

Xenetic Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIO Xenetic Biosciences	1.0511 of 5 stars	$2.77 +12.6%	N/A	-11.5%	$6.35M	$3.26M	N/A	2	News Coverage High Trading Volume
ATNM Actinium Pharmaceuticals	2.681 of 5 stars	$1.24 -0.8%	$5.00 +303.2%	-23.3%	$38.99M	$35.09M	N/A	30	News Coverage Analyst Revision
ATYR aTyr Pharma	0.621 of 5 stars	$0.38 -1.3%	N/A	-63.4%	$38.18M	$190K	N/A	53	Analyst Downgrade
CELU Celularity	0.1943 of 5 stars	$1.29 +4.0%	N/A	-41.0%	$35.89M	$26.55M	N/A	220
CNTX Context Therapeutics	2.3865 of 5 stars	$0.38 +4.0%	$6.17 +1,527.1%	-62.0%	$33.48M	N/A	N/A	7	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenetic Biosciences (XBIO) Competitors

XBIO vs. ATNM, ATYR, CELU, CNTX, and MDXH

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Summary

How does Xenetic Biosciences compare to aTyr Pharma?

Summary

How does Xenetic Biosciences compare to Celularity?

Summary

How does Xenetic Biosciences compare to Context Therapeutics?

Summary

How does Xenetic Biosciences compare to MDxHealth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenetic Biosciences (XBIO) Competitors

XBIO vs. ATNM, ATYR, CELU, CNTX, and MDXH

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Does the media refer more to XBIO or ATNM?

Which has stronger valuation & earnings, XBIO or ATNM?

Do analysts recommend XBIO or ATNM?

Do insiders and institutionals have more ownership in XBIO or ATNM?

Which has more volatility and risk, XBIO or ATNM?

Is XBIO or ATNM more profitable?

Summary

How does Xenetic Biosciences compare to aTyr Pharma?

Do insiders & institutionals believe in XBIO or ATYR?

Is XBIO or ATYR more profitable?

Do analysts rate XBIO or ATYR?

Does the media refer more to XBIO or ATYR?

Which has more volatility and risk, XBIO or ATYR?

Which has stronger earnings & valuation, XBIO or ATYR?

Summary

How does Xenetic Biosciences compare to Celularity?

Which has stronger valuation and earnings, CELU or XBIO?

Is CELU or XBIO more profitable?

Which has more risk and volatility, CELU or XBIO?

Do insiders and institutionals believe in CELU or XBIO?

Does the media favor CELU or XBIO?

Do analysts prefer CELU or XBIO?

Summary

How does Xenetic Biosciences compare to Context Therapeutics?

Which has more volatility and risk, CNTX or XBIO?

Do analysts prefer CNTX or XBIO?

Do institutionals & insiders hold more shares of CNTX or XBIO?

Does the media favor CNTX or XBIO?

Is CNTX or XBIO more profitable?

Which has higher valuation & earnings, CNTX or XBIO?

Summary

How does Xenetic Biosciences compare to MDxHealth?

Which has more volatility & risk, XBIO or MDXH?

Which has higher valuation and earnings, XBIO or MDXH?

Do insiders & institutionals believe in XBIO or MDXH?

Does the media prefer XBIO or MDXH?

Is XBIO or MDXH more profitable?

Do analysts prefer XBIO or MDXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools